Payment overview · 2025
General Payments
$388.74
19 reported records · 8 companies
Healthcare provider profile · identity verified
Corey Gallus, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · UNION, KY · NPI 1457333502
Verified facts
What the public records show
CMS Open Payments records show Corey Gallus, D.O. received $388.74 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.04 | 28.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.43 | 18.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $67.85 | 17.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.75 | 13.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.11 | 8.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.88 | 5.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.38 | 4.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.30 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.74 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.02 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $67.85 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.90 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.11 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.11 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 527 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 127 |
| Omeprazole | Omeprazole | 376 | 108 |
| Lisinopril | Lisinopril | 343 | 95 |
| Simvastatin | Simvastatin | 291 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 72 |
| Valsartan | Valsartan | 241 | 71 |
| Montelukast Sodium | Montelukast Sodium | 230 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 49 |
| Losartan Potassium | Losartan Potassium | 173 | 49 |
| Carvedilol | Carvedilol | 160 | 47 |
| Metformin Hcl Er | Metformin Hcl | 150 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 50 |
| Trazodone Hcl | Trazodone Hcl | 138 | 44 |
| Furosemide | Furosemide | 131 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 117 | 34 |
| Sertraline Hcl | Sertraline Hcl | 113 | 32 |
| Alendronate Sodium | Alendronate Sodium | 110 | 34 |
| Gabapentin | Gabapentin | 109 | 27 |
| Metformin Hcl | Metformin Hcl | 99 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 26 |
| Bupropion Xl | Bupropion Hcl | 97 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 18 |
| Allopurinol | Allopurinol | 83 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 36 |
| Levofloxacin | Levofloxacin | 72 | 61 |
| Eliquis | Apixaban | 69 | 14 |
| Buspirone Hcl | Buspirone Hcl | 67 | 16 |
| Eszopiclone | Eszopiclone | 67 | 16 |
| Ezetimibe | Ezetimibe | 67 | 15 |
| Mirtazapine | Mirtazapine | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Meloxicam | Meloxicam | 64 | 20 |
| Potassium Chloride | Potassium Chloride | 64 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 17 |
| Tramadol Hcl | Tramadol Hcl | 59 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Spironolactone | Spironolactone | 58 | 18 |
| Azithromycin | Azithromycin | 57 | 50 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 24 |
| Cephalexin | Cephalexin | 53 | 27 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Prednisone | Prednisone | 53 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 31 |
| Jardiance | Empagliflozin | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 16 |
| Finasteride | Finasteride | 46 | 16 |
| Glimepiride | Glimepiride | 46 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 43 | 12 |
| Celecoxib | Celecoxib | 42 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 16 |
| Atenolol | Atenolol | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 21 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cefprozil | Cefprozil | 15 | 14 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.74 · 19 records | ABBVIE INC. | FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error